Stocktoria
BioXcel Therapeutics, Inc. BTAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-08
BioXcel Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — |
| R&D expense | $30.3M | $30.4M | $84.3M | $91.2M | $52.7M |
| SG&A expense | $20.5M | $34.5M | $83.4M | $68.8M | $54.2M |
| Operating income | -$50.5M | -$67.2M | -$171.8M | -$159.6M | -$106.9M |
| Interest expense | — | — | $13.3M | $8.2M | $40,000 |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$69.9M | -$59.6M | -$179.1M | -$165.8M | -$106.9M |
| EPS (diluted) | $-5.73 | $-23.51 | $-98.33 | $-5.92 | $-4.05 |
| Operating cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.3M | -$82.2M |
| Free cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.5M | -$82.6M |
| Cash & equivalents | $28.4M | $29.9M | $65.2M | $193.7M | $233.0M |
| Inventory | $722,000 | $679,000 | $2.0M | $2.0M | — |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M |
| Shareholders' equity | -$95.5M | -$93.1M | -$56.5M | $76.8M | $221.7M |
Source: SEC EDGAR filings · CIK 0001720893 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.